Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
2
40%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

completed240%
recruiting120%
unknown120%
active_not_recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

NCT04945330
completedphase_1

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913
active_not_recruitingphase_1

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

NCT02637687
completed

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

NCT05236257
unknown

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

NCT03025360

Clinical Trials (5)

Showing 5 of 5 trials
NCT04945330

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Recruiting
NCT02122913Phase 1

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Completed
NCT02637687Phase 1

A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

Active Not Recruiting
NCT05236257

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

Completed
NCT03025360

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5